New hope for Hard-to-Treat myeloma: Real-World study launches
NCT ID NCT07559799
First seen Apr 30, 2026 · Last updated Jun 06, 2026 · Updated 8 times
Summary
This study looks at how well the drug combination melflufen (Pepaxti®) and dexamethasone works in everyday medical practice for people with multiple myeloma that has come back or stopped responding to other treatments. About 50 participants will be observed to see how long the disease is controlled. The goal is to gather real-world information to help doctors manage this advanced stage of the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.